An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
Clinical trial NCT03897881 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03897881
- Sponsor
- ModernaTX, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-18
- Primary completion
- 2032-11-30
- Enrollment
- 267
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.